Substance abuse in hospitalized psychiatric patients

Israel Medical Association Journal

Volumn 10, Issue 10, 2008, Pages 672-675

  Katz, Gregory ^a   Durst, Rimona ^a   Shufman, Emi ^a   Bar Hamburger, Rachel ^b   Grunhaus, Leon ^a,c  

^a Jerusalem Mental Health Center Ezrath Nashim   (Israel)

^b Israel Anti Drug Authority   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

Epidemiology; Hospitalized psychiatric patients; Major mental problems; Substance abuse

Indexed keywords

AMPHETAMINE; CANNABIS; COCAINE; METHAMPHETAMINE; OPIATE; CENTRAL STIMULANT AGENT;

ADULT; AGED; ARTICLE; COMORBIDITY; DEMOGRAPHY; FEMALE; GENERAL HOSPITAL; HUMAN; ISRAEL; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL HEALTH CENTER; MENTAL HOSPITAL; PREVALENCE; PSYCHIATRIC DEPARTMENT; SELF REPORT; SUBSTANCE ABUSE; ADOLESCENT; AGE DISTRIBUTION; CANNABIS ADDICTION; CLINICAL TRIAL; COMPARATIVE STUDY; HOSPITAL PATIENT; MIDDLE AGED; MULTICENTER STUDY; OPIATE ADDICTION; RETROSPECTIVE STUDY; RISK FACTOR; SEX RATIO;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; CENTRAL NERVOUS SYSTEM STIMULANTS; FEMALE; HUMANS; INPATIENTS; ISRAEL; MALE; MARIJUANA ABUSE; MENTAL DISORDERS; MIDDLE AGED; OPIOID-RELATED DISORDERS; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SEX DISTRIBUTION; YOUNG ADULT;

EID: 58149168922     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Margolese HS, Malchy L, Negrete JS, Tempier R, Gill K. Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences. Schizophr Res 2004;67(2-3): 157-166 (Pubitemid 38251445)
2. Fowler IL, Carr VJ, Carter NT, Levin TJ. Patterns of current and lifetime substance use in schizophrenia. Schizophr Bull 1998;24(3):443-455 (Pubitemid 28378229)
3. Cantwell R, Brewin J, Glazebrook C, et al. Prevalence of substance misuse in first-episode psychosis. Br J Psychiatry 1999;174:150-153 (Pubitemid 29089289)
4. Swartz MS, Wagner HR, Swanson JW, et al. Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study. Psychiatr Serv 2006;57(8):1110-1116
5. Knobler H, Katz G, Srur N, Maizel S, Margolin Y, Lerner Y. Substance abuse among mental patients. Harefuah 1992;122(11):692-4, 752 (Hebrew).
6. Katz G, Shufman E, Knobler HY, Ioffe M, Bar-Hamburger R, Durst R. Drug abuse among patients requiring psychiatric hospitalization. Harefuah 2000;138(12):1015-18, 1088 (Hebrew).
7. Hickman M, Vickerman P, Macleod J, Kirkbride J, Jones PB. Cannabis and schizophrenia: model projections of the impact of the rise in cannabis use on historical and future trends in schizophrenia in England and Wales. Addiction 2007;102(4):597-606. (Pubitemid 46398826)
8. Swofford CD, Scheller-Gilkey G, Miller AH, Woolwine B, Mance R. Double jeopardy: schizophrenia and substance use. Am J Drug Alcohol Abuse 2000;26(3):343-353 (Pubitemid 30667001)
9. Thorup A, Petersen L, Jeppesen P, et al. Gender differences in young adults with first-episode schizophrenia spectrum disorders at baseline in the Danish OPUS study. J Nerv Ment Dis 2007;195(5):396-405. (Pubitemid 46763241)
10. de Beaurepaire R, Lukasiewicz M, Beauverie P, et al. Comparison of self-reports and biological measures for alcohol, tobacco, and illicit drugs consumption in psychiatric inpatients. Eur Psychiatry 2007;2(8):540-548
11. Green AI, Brown ES. Comorbid schizophrenia and substance abuse. J Clin Psychiatry 2006;67(9):e08.
12. Arendt M, Rosenberg R, Foldager L, Perto G, Munk-Jorgensen P. Psychopathology among cannabis-dependent treatment seekers and association with later substance abuse treatment. J Subst Abuse Treat 2007;32(2):113-119 (Pubitemid 46240716)
13. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007;28;370(9584):319-328
14. Selten JP, Veen ND, Hoek HW, et al. Early course of schizophrenia in a representative Dutch incidence cohort. Schizophr Res 2007;97(1-3):79-87.
15. Johns A. Psychiatric effects of cannabis. Br J Psychiatry 2001;178:116-122
16. Skosnik PD, Krishman GP, Aydt EE, Kushlenshmidt NA, O'Donnell BF. Psychophysiological evidence of altered neural synchronization in cannabis use: relationship to schizotypy. Am J Psychiatry 2006;163(10):1798-1805
17. Ashton CH, Moore BP, Gallagher P, Young AH. Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential. J Psychopharmacol 2005;19(3):293-300. (Pubitemid 40694948)
18. Calle PA, Damen J, De Paepe P, Monsieurs KG, Buylaert WA. A survey on alcohol and illicit drug abuse among emergency department patients. Acta Clin Belg 2006;61(4):188-195 (Pubitemid 44577271)
19. MacKetin R, MacLaren J, Lubman DI, Hides L. The prevalence of psychotic symptoms among methamphetamine users. Addiction 2006;101(10):1473-1478 (Pubitemid 44337772)
20. Gulliot C. Is recreational ecstasy (MDMA) use associated with higher levels of depressive symptoms? J Psychoactive Drugs 2007;39(1):31-39
21. Jaffe A, Shoptaw S, Stein J, Reback CJ, Rotheram-Fuller E. Depression ratings, reported sexual risk behaviors, and methamphetamine use: latent growth curve models of positive change among gay and bisexual men in an outpatient treatment program. Exp Clin Psyhopharmarcol 2007;15(3):301-307
22. Nolen WA, Luckenbaugh DA, Altshuler LL, et al. Correlates of 1-year prospective outcome in bipolar disorder: results from the Stanley Foundation Bipolar Network. Am J Psychiatry 2004;161(8):1447-1454
23. Dalmau A, Bergman B, Brismar B. Psychotic disorders among inpatients with abuse of cannabis, amphetamine and opiates. Do dopaminergic stimulants facilitate psychiatric illness? Eur Psychiatry 1999;14(7):366-371